|
(5) ¿ÍÀÎÀå ¿ù³Ó
|
|
![](image/board_answer_img_01.gif) |
JqYigtQoDoHTC |
![](image/board_answer_img_04.gif) |
177 |
|
![](image/board_line2.gif) |
I can't get a signal http://xnxx-xnxxvideo.in.net/ xnxx cina The researchers found that the 10-year biochemical recurrence-free survival was 42.9%, 25.1%, and 28.6% for patients who had biopsy Gleason 8, 9, and 10 tumors, respectively. The 10-year clinical progression-free survival was 70.7%, 47.2%, and 25%, respectively. The 10-year cancer-specific survival was 84.9%, 66.1%, and 50%. After adjusting for preoperative PSA level, clinical T stage, and age, men with a biopsy Gleason score of 9 and 10 had an approximately 2.5 and 4.0 times higher risk for clinical progression and cancer-related death compared with men who had a biopsy Gleason score of 8. |
![](image/board_line2.gif) |
![](image/board_answer_img_02.gif) |
Chris |
![](image/board_answer_img_03.gif) |
2019-09-17 11:39:37 |
|
|
|
|
|
|
|
|